Heart Failure Nursing Diagnosis: A Comprehensive Guide for Cardiovascular Nurses

Introduction

Heart failure (HF) is a prevalent and intricate clinical syndrome arising from any structural or functional cardiac disorder. This condition impairs the heart’s ability to effectively fill with or eject blood, thereby failing to meet the body’s systemic circulatory demands. Numerous diseases can lead to heart failure, but the majority of patients experience symptoms stemming from compromised left ventricular myocardial function. Common patient presentations include dyspnea, fatigue, reduced exercise tolerance, and fluid retention, manifesting as pulmonary and peripheral edema.[1]

Heart failure due to left ventricular dysfunction is classified by left ventricular ejection fraction (LVEF) into two primary categories: heart failure with reduced ejection fraction (HFrEF), where LVEF is 40% or less, and heart failure with preserved ejection fraction (HFpEF), where LVEF is greater than 40%.[2] Understanding these classifications is crucial for accurate Cardiovascular Nursing Diagnosis and effective patient management.

Common Cardiovascular Nursing Diagnoses for Heart Failure

Cardiovascular nurses play a pivotal role in the care of patients with heart failure. Accurate nursing diagnoses are essential to guide individualized care plans and improve patient outcomes. Based on the pathophysiology and clinical manifestations of heart failure, several key nursing diagnoses are frequently identified:

• Decreased Cardiac Output: This diagnosis addresses the heart’s inability to pump sufficient blood to meet the body’s metabolic needs.
• Activity Intolerance: Related to the imbalance between oxygen supply and demand, leading to fatigue and shortness of breath with exertion.
• Excess Fluid Volume: Characterized by fluid retention in interstitial and intravascular spaces, often manifesting as edema and pulmonary congestion.
• Risk for Impaired Skin Integrity: Edema and poor tissue perfusion increase the risk of skin breakdown and pressure ulcers.
• Ineffective Tissue Perfusion: Reflects inadequate blood flow to peripheral tissues, potentially leading to ischemia and organ dysfunction.
• Ineffective Breathing Pattern: Associated with pulmonary congestion and fluid overload, resulting in dyspnea and orthopnea.
• Impaired Gas Exchange: Compromised alveolar-capillary exchange due to pulmonary edema, leading to hypoxemia.
• Fatigue: A pervasive symptom of heart failure, stemming from reduced cardiac output and metabolic imbalances.
• Anxiety: Commonly experienced due to dyspnea, discomfort, and the chronic nature of heart failure.

These cardiovascular nursing diagnoses provide a framework for addressing the complex needs of patients with heart failure and guiding nursing interventions.

Etiology of Heart Failure

Heart failure is not a disease itself but a syndrome resulting from various underlying conditions that impair heart function. These conditions can affect different parts of the heart and cardiovascular system, including the pericardium, myocardium, endocardium, cardiac valves, vasculature, or cardiac metabolism.

The most prevalent causes of systolic dysfunction (HFrEF) include:

• Idiopathic Dilated Cardiomyopathy (DCM): A condition where the heart chambers enlarge and weaken without a clear identifiable cause.[44]
• Coronary Heart Disease (Ischemic Heart Disease): Reduced blood flow to the heart muscle due to narrowed coronary arteries, often leading to myocardial infarction and subsequent heart failure.[38]
• Hypertension: Chronic high blood pressure places excessive strain on the heart, leading to left ventricular hypertrophy and eventually heart failure.[25],[26]
• Valvular Heart Disease: Conditions affecting the heart valves, such as stenosis or regurgitation, can disrupt normal blood flow and lead to heart failure.[1]

For diastolic dysfunction (HFpEF), common causes are similar and include:

• Hypertension: A major contributor to HFpEF, as it leads to stiffening of the left ventricle, impairing its ability to relax and fill properly.[34],[35]
• Hypertrophic Obstructive Cardiomyopathy: A genetic condition characterized by thickening of the heart muscle, which can obstruct blood flow and impair diastolic function.[1]
• Restrictive Cardiomyopathy: A condition where the heart muscle becomes stiff and less elastic, hindering ventricular filling.[8],[10]

Other less common but significant causes of heart failure include myocarditis (inflammation of the heart muscle), pericardial diseases, congenital heart defects, and certain systemic diseases.

Risk Factors for Heart Failure

Several modifiable and non-modifiable risk factors increase the likelihood of developing heart failure. Identifying these risk factors is crucial for preventive strategies and patient education.

Key risk factors include:

• Coronary Artery Disease (CAD): The most significant risk factor, as CAD can lead to myocardial infarction and ischemic cardiomyopathy.[27],[28]
• Myocardial Infarction (MI): Heart attack damages heart muscle, often leading to reduced ejection fraction and heart failure.[38]
• Hypertension: Long-term hypertension significantly increases the workload on the heart, predisposing individuals to heart failure.[25],[26]
• Diabetes Mellitus: Diabetes contributes to cardiovascular disease and cardiomyopathy, increasing heart failure risk.[17]
• Obesity: Excess body weight strains the heart and is associated with other risk factors like hypertension and diabetes.[17]
• Smoking: Smoking damages blood vessels and increases the risk of CAD and hypertension, thereby elevating heart failure risk.[27]
• Alcohol Use Disorder: Excessive alcohol consumption can lead to alcoholic cardiomyopathy and heart failure.[1]
• Atrial Fibrillation: This common arrhythmia can impair heart function and contribute to heart failure, and vice versa.[18]
• Thyroid Diseases: Both hyperthyroidism and hypothyroidism can affect cardiac function and increase heart failure risk.[19]
• Congenital Heart Disease: Structural heart defects present at birth can lead to heart failure later in life.[1]
• Aortic Stenosis: Narrowing of the aortic valve increases the heart’s workload and can cause heart failure.[1]

Managing modifiable risk factors through lifestyle changes and medical interventions is crucial in preventing or delaying the progression of heart failure.

Assessment of Heart Failure: Recognizing Signs and Symptoms

A comprehensive assessment is vital for accurate cardiovascular nursing diagnosis and effective management of heart failure. Symptoms can be broadly categorized into those resulting from fluid overload and those from reduced cardiac output.

Symptoms due to Excess Fluid Accumulation:

• Dyspnea (Shortness of Breath): Especially on exertion or lying flat (orthopnea), due to pulmonary congestion.[1]
• Orthopnea: Difficulty breathing when lying down, relieved by sitting or standing.[1]
• Edema: Swelling in the ankles, legs, abdomen (ascites), and sacral area due to fluid retention.[31]
• Hepatic Congestion: Enlargement and tenderness of the liver due to fluid backup in the venous system, causing right upper quadrant pain.[1]
• Abdominal Distension: Increased abdominal girth due to ascites and bowel edema.[1]

Symptoms due to Reduced Cardiac Output:

• Fatigue: Persistent tiredness and lack of energy, often worsening with physical activity.[1]
• Weakness: Generalized muscle weakness due to inadequate oxygen delivery to tissues.[1]
• Decreased Exercise Tolerance: Inability to perform usual activities due to shortness of breath and fatigue.[1]

Clinical Presentations:

• Acute and Subacute Presentations (Days to Weeks): Characterized by rapid onset of shortness of breath at rest or with exertion, orthopnea, paroxysmal nocturnal dyspnea (sudden nighttime breathlessness), and right upper quadrant discomfort.[1] Palpitations and lightheadedness may occur due to arrhythmias.
• Chronic Presentations (Months): Fatigue, anorexia, abdominal distension, and peripheral edema may be more prominent than dyspnea. Anorexia can be caused by poor splanchnic circulation, bowel edema, and hepatic congestion-induced nausea.[1]

Characteristic Physical Examination Findings:

• Pulsus Alternans: Alternating strong and weak peripheral pulses, indicating severe left ventricular dysfunction.[1]
• Displaced Apical Impulse: Apical impulse shifted laterally past the midclavicular line, suggesting left ventricular enlargement.[1]
• S3 Gallop: A low-frequency heart sound in early diastole, a highly sensitive indicator of ventricular dysfunction.[1]
• Peripheral Edema: Visible swelling in the extremities.[1]
• Pulmonary Rales (Crackles): Abnormal lung sounds indicating fluid in the alveoli.[1]

New York Heart Association (NYHA) Functional Classification:

The NYHA classification system categorizes heart failure severity based on symptom presentation and activity level:

• Class I: Symptoms only occur with more than ordinary physical activity.
• Class II: Symptoms occur with ordinary physical activity.
• Class III: Symptoms occur with minimal physical activity.
• Class IV: Symptoms are present even at rest.

This classification is a valuable tool for assessing disease progression and guiding treatment strategies.

Diagnostic Evaluation for Heart Failure

Several diagnostic tests are employed to evaluate patients with suspected heart failure, aiding in confirming the cardiovascular nursing diagnosis and determining the underlying cause and severity.

• Electrocardiogram (ECG): Detects evidence of myocardial infarction, ischemia, rhythm abnormalities like atrial fibrillation, and left ventricular hypertrophy.[1]
• Chest X-ray: Reveals cardiac enlargement (cardiac-to-thoracic ratio > 50%), pulmonary vascular congestion (cephalization), interstitial edema (Kerley B-lines), and pleural effusions.[1]

Chest radiograph illustrating signs of congestive heart failure, including cardiac enlargement and pulmonary edema.

• Blood Tests:
  • Cardiac Troponin (T or I): Elevated levels indicate myocardial injury, helpful in ruling out acute myocardial infarction.[1]
  • Complete Blood Count (CBC): Assesses overall health and can identify anemia, which can exacerbate heart failure symptoms.[1]
  • Serum Electrolytes (Sodium, Potassium): Detects electrolyte imbalances, which are common in heart failure and can affect cardiac function and medication management.[39]
  • Blood Urea Nitrogen (BUN) and Creatinine: Assess renal function, which is often impaired in heart failure and influenced by medications.[1]
  • Liver Function Tests (LFTs): Evaluate liver congestion and dysfunction due to heart failure.[1]
  • Brain Natriuretic Peptide (BNP) or N-terminal pro-BNP (NT-proBNP): Elevated levels are highly sensitive and specific for heart failure, aiding in diagnosis and prognosis.[41]
• Transthoracic Echocardiogram (TTE): The cornerstone of heart failure evaluation, providing detailed information on ventricular function, ejection fraction, valve function, and hemodynamics.[1]

These tests, in conjunction with clinical assessment, are essential for establishing a definitive diagnosis of heart failure and guiding appropriate medical and nursing management.

Medical Treatment Strategies for Heart Failure

Medical management of heart failure aims to alleviate symptoms, improve quality of life, reduce hospitalizations, and prolong survival. Pharmacological and device therapies are integral components of this management.

Pharmacological Management:

Several classes of medications are used in heart failure management, often in combination, to target different aspects of the pathophysiology:

• Diuretics: Such as furosemide and hydrochlorothiazide, reduce fluid overload and alleviate symptoms like edema and dyspnea.[1]
• Beta-blockers: Like metoprolol and carvedilol, reduce heart rate and blood pressure, improve left ventricular function, and reduce mortality in HFrEF.[3],[47]
• Angiotensin-Converting Enzyme Inhibitors (ACEIs): Such as enalapril and lisinopril, reduce blood pressure and afterload, improve symptoms, and reduce mortality in HFrEF.[3],[47]
• Angiotensin Receptor Blockers (ARBs): Like valsartan and losartan, used as alternatives to ACEIs, providing similar benefits in HFrEF.[3],[47]
• Angiotensin Receptor-Neprilysin Inhibitors (ARNIs): Such as sacubitril/valsartan, combine an ARB with a neprilysin inhibitor, demonstrating superior outcomes compared to ACEIs in HFrEF.[32],[33]
• Hydralazine and Nitrate Combination: Particularly beneficial in African-American patients with persistent NYHA class III-IV HFrEF despite optimal therapy, improves vasodilation and reduces afterload.[3]
• Digoxin: Increases cardiac contractility and can help control heart rate in certain patients, primarily for symptom management.[1]
• Aldosterone Antagonists (Mineralocorticoid Receptor Antagonists – MRAs): Such as spironolactone and eplerenone, reduce fluid retention, potassium loss, and mortality in HFrEF.[3],[47]
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Newer agents like empagliflozin and dapagliflozin, initially developed for diabetes, have shown significant benefits in reducing heart failure hospitalizations and cardiovascular mortality in both HFrEF and HFpEF.[47]
• Vericiguat: A soluble guanylate cyclase stimulator, used in HFrEF to reduce the risk of cardiovascular death and heart failure hospitalization after a worsening heart failure event.[46],[47]

Device Therapy:

• Implantable Cardioverter-Defibrillator (ICD): Prevents sudden cardiac death in patients at high risk of ventricular arrhythmias, indicated for primary and secondary prevention.[3]
• Cardiac Resynchronization Therapy (CRT): Biventricular pacing improves heart function and symptoms in selected patients with reduced LVEF and prolonged QRS duration, often combined with an ICD (CRT-D).[3]
• Ventricular Assist Device (VAD): Mechanical pump supporting heart function, used as a bridge to transplant or destination therapy in severe heart failure.[1]
• Cardiac Transplantation: Considered for end-stage heart failure patients who are not responding to other therapies.[1]

The choice of medical and device therapy is individualized based on the patient’s NYHA functional class, LVEF, comorbidities, and overall clinical status.

Nursing Care and Management of Heart Failure

Nursing management is crucial for patients with heart failure, focusing on symptom relief, education, and promoting self-care. The nursing care plan should address the identified cardiovascular nursing diagnoses and encompass the following key aspects:[4]

• Relieving Fluid Overload Symptoms: Administer diuretics as prescribed, monitor fluid balance, and educate patients on sodium and fluid restriction.
• Alleviating Anxiety and Fatigue: Implement strategies to reduce anxiety, promote rest, and manage fatigue through energy conservation techniques.
• Promoting Physical Activity: Encourage regular, moderate exercise as tolerated, to improve functional capacity and quality of life.
• Enhancing Medication Compliance: Educate patients about their medications, side effects, and the importance of adherence.
• Minimizing Adverse Effects of Treatment: Monitor for and manage potential side effects of medications, such as electrolyte imbalances and hypotension.
• Patient Education on Dietary Restrictions: Provide detailed instructions on sodium and fluid restrictions, emphasizing their role in symptom management.
• Teaching Self-Monitoring of Symptoms: Educate patients on recognizing and reporting worsening symptoms, such as increased dyspnea, edema, or weight gain.
• Daily Weight Monitoring Education: Instruct patients on the importance of daily weight monitoring and when to report significant changes.

When to Seek Immediate Medical Attention

Patients with heart failure need to be educated on recognizing worsening symptoms that require prompt medical evaluation. Immediate assessment is indicated in situations such as:

• Worsening Fluid Overload Symptoms: Rapid weight gain, increased edema, worsening dyspnea or orthopnea.
• Worsening Hypoxia: Increased shortness of breath, especially at rest, or new onset of cyanosis.
• Uncontrolled Tachycardia: Rapid heart rate that does not resolve, regardless of rhythm.
• Changes in Cardiac Rhythm: New onset of palpitations or irregular heartbeats.
• Change in Mental Status: Confusion, dizziness, or lightheadedness.
• Decreased Urinary Output: Significant reduction in urine production despite diuretic use.

Prompt recognition and reporting of these symptoms can prevent acute decompensation and improve patient outcomes.

Ongoing Monitoring for Heart Failure Patients

Regular monitoring is essential for managing heart failure effectively and detecting early signs of deterioration. This includes:

• Vital Signs Monitoring: Frequent assessment of blood pressure, heart rate, respiratory rate, and oxygen saturation.
• Telemetry Monitoring: Continuous heart rate and rhythm monitoring, especially during hospitalizations or periods of instability.
• Symptom Assessment: Regularly evaluate for changes in dyspnea, edema, fatigue, and other heart failure symptoms.
• Daily Weight Monitoring: Essential for detecting fluid retention and guiding diuretic therapy adjustments.

Interprofessional Coordination of Care

Optimal heart failure management necessitates a collaborative approach involving an interprofessional team. Key team members include:

• Primary Care Physician: Provides ongoing primary care and coordinates specialist referrals.
• Emergency Department Physician: Manages acute decompensations and initiates urgent treatment.
• Cardiologist: Specializes in heart failure management, guides medical and device therapies.
• Radiologist: Interprets chest X-rays and other imaging studies.
• Cardiac Nurses: Provide specialized nursing care, patient education, and symptom management.
• Internist: Manages co-existing medical conditions.
• Cardiac Surgeons: Perform surgical interventions like cardiac transplantation or VAD implantation.

Effective communication and collaboration among these professionals are crucial to ensure comprehensive and coordinated care for patients with heart failure. Patient education on medication adherence and lifestyle modifications is also paramount, often led by clinical nurses.

Health Education and Promotion for Heart Failure

Patient education is a cornerstone of heart failure nursing care, aimed at improving clinical outcomes and reducing hospital readmissions. Key areas of health teaching include:

• Self-Monitoring of Symptoms: Educating patients on how to recognize and track symptoms at home.
• Medication Compliance: Providing detailed instructions on medication regimens, timing, and potential side effects.
• Daily Weight Monitoring: Teaching proper techniques for daily weighing and interpreting weight changes.
• Dietary Sodium Restriction: Guiding patients on limiting sodium intake to 2-3 grams per day.
• Daily Fluid Restriction: Advising patients to restrict fluid intake to 2 liters per day, as recommended.
• Risk Factor Management: Encouraging aggressive management of underlying risk factors like diabetes, hypertension, obesity, smoking, and alcohol use.
• Sleep Apnea Management: Promoting CPAP therapy for patients with sleep apnea and heart failure to improve outcomes.

Discharge Planning for Heart Failure Patients

Effective discharge planning is crucial to ensure a smooth transition from hospital to home and prevent readmissions. Discharge planning should encompass:

• Medication Management: Detailed review of medications, dosages, and administration instructions.
• Medication Compliance Strategies: Reinforcing the importance of adherence and providing tools to aid compliance.
• Low-Sodium Diet and Fluid Restriction Guidelines: Reiterating dietary and fluid restrictions.
• Activity and Exercise Recommendations: Providing personalized recommendations for physical activity.
• Smoking Cessation Support: Offering resources and support for smoking cessation.
• Recognition of Worsening Heart Failure Signs and Symptoms: Reviewing key symptoms that warrant medical attention.
• Follow-up Appointments: Scheduling timely follow-up appointments to ensure ongoing medical management.

Nurse-driven education at discharge has been shown to significantly improve patient compliance and outcomes in heart failure.

Conclusion

Heart failure is a complex and chronic condition requiring comprehensive and ongoing management. Cardiovascular nurses are integral to the care of these patients, utilizing their expertise in cardiovascular nursing diagnosis to guide individualized care plans. By understanding the pathophysiology, risk factors, assessment findings, and management strategies for heart failure, nurses can significantly impact patient outcomes, improve quality of life, and reduce hospital readmissions. Effective patient education, interprofessional collaboration, and diligent monitoring are essential components of high-quality cardiovascular nursing care for individuals living with heart failure.

References

1.Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW., ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 03;145(18):e895-e1032. [PubMed: 35363499]

2.Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78. [PMC free article: PMC4868779] [PubMed: 26935038]

3.CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 04;316(23):1429-35. [PubMed: 2883575]

4.Lind L, Ingelsson M, Sundstrom J, Ärnlöv J. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Heart. 2021 Sep;8(2) [PMC free article: PMC8438838] [PubMed: 34518286]

5.Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019 Nov 19;9(1):17022. [PMC free article: PMC6863880] [PubMed: 31745178]

6.Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circ J. 2021 Oct;51(10):797-836. [PMC free article: PMC8484993] [PubMed: 34327881]

7.Rezkalla SH, Kloner RA. Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics. Trends Cardiovasc Med. 2021 Apr;31(3):163-169. [PMC free article: PMC7965406] [PubMed: 33383171]

8.Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 15;121(7):819-837. [PubMed: 28912185]

9.Shams P, Ahmed I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Cardiac Amyloidosis. [PubMed: 35593829]

10.Brown KN, Pendela VS, Ahmed I, Diaz RR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Restrictive Cardiomyopathy. [PubMed: 30725919]

11.Matta AG, Carrié D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med Sci Monit. 2023 Mar 06;29:e939020. [PMC free article: PMC9999670] [PubMed: 36872594]

12.Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr;39:100990. [PMC free article: PMC8913320] [PubMed: 35281752]

13.Ahmad SA, Brito D, Khalid N, Ibrahim MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Takotsubo Cardiomyopathy. [PubMed: 28613549]

14.DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CSP, Hsich E. Heart Failure Subtypes and Cardiomyopathies in Women. Circ Res. 2022 Feb 18;130(4):436-454. [PMC free article: PMC10361647] [PubMed: 35175847]

15.Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013 Nov 12;62(20):1845-54. [PubMed: 23850914]

16.Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, Piepoli MF. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):46-51. [PMC free article: PMC7691623] [PubMed: 33238736]

17.Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. [PMC free article: PMC10040794] [PubMed: 36993998]

18.Kim DY, Kim SH, Ryu KH. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019 Sep;49(9):808-817. [PMC free article: PMC6713829] [PubMed: 31456374]

19.Anakwue RC, Onwubere BJ, Anisiuba BC, Ikeh VO, Mbah A, Ike SO. Congestive heart failure in subjects with thyrotoxicosis in a black community. Vasc Health Risk Manag. 2010 Aug 09;6:473-7. [PMC free article: PMC2922308] [PubMed: 20730063]

20.Schoenenberger AW, Schoenenberger-Berzins R, der Maur CA, Suter PM, Vergopoulos A, Erne P. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. Clin Res Cardiol. 2012 Mar;101(3):159-64. [PubMed: 22057652]

21.DiNicolantonio JJ, Liu J, O’Keefe JH. Thiamine and Cardiovascular Disease: A Literature Review. Prog Cardiovasc Dis. 2018 May-Jun;61(1):27-32. [PubMed: 29360523]

22.Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016 Aug 02;68(5):473-482. [PubMed: 27470455]

23.Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014 Jul;8(3):308-15. [PMC free article: PMC4160726] [PubMed: 25221635]

24.Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 03;141(9):e139-e596. [PubMed: 31992061]

25.Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A. [PubMed: 8376698]

26.Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 07;135(10):e146-e603. [PMC free article: PMC5408160] [PubMed: 28122885]

27.Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F, Oguz A, Kruger IM, Diaz R, Yusoff K, Mony P, Chifamba J, Yeates K, Kelishadi R, Yusufali A, Khatib R, Rahman O, Zatonska K, Iqbal R, Wei L, Bo H, Rosengren A, Kaur M, Mohan V, Lear SA, Teo KK, Leong D, O’Donnell M, McKee M, Dagenais G. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 07;395(10226):795-808. [PMC free article: PMC8006904] [PubMed: 31492503]

28.Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006 Jan 28;367(9507):356-67. [PubMed: 16443044]

29.Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. [PubMed: 22227365]

30.Ait Mou Y, Bollensdorff C, Cazorla O, Magdi Y, de Tombe PP. Exploring cardiac biophysical properties. Glob Cardiol Sci Pract. 2015;2015:10. [PMC free article: PMC4448074] [PubMed: 26779498]

31.Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. [PMC free article: PMC9553007] [PubMed: 36237903]

32.Prausmüller S, Arfsten H, Spinka G, Freitag C, Bartko PE, Goliasch G, Strunk G, Pavo N, Hülsmann M. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. J Am Heart Assoc. 2020 Jun 02;9(11):e015071. [PMC free article: PMC7428996] [PubMed: 32427034]

33.Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800-810. [PMC free article: PMC8837825] [PubMed: 33004114]

34.Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):245-257. [PMC free article: PMC6899218] [PubMed: 31202759]

35.Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35. [PMC free article: PMC4654630] [PubMed: 26250359]

36.Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 Jul;19(7):821-836. [PMC free article: PMC5734941] [PubMed: 28560717]

37.King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. Am Fam Physician. 2012 Jun 15;85(12):1161-8. [PubMed: 22962896]

38.Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja F, Sabbah HN, Goldstein S. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J. 1999 Dec;138(6 Pt 1):1133-9. [PubMed: 10577445]

39.Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF, Califf RM, Gheorghiade M., OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005 May 17;111(19):2454-60. [PubMed: 15867182]

40.Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73. [PubMed: 22104551]

41.Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, Køber L, Prescott MF, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 Feb;13(2):e006541. [PubMed: 32065760]

42.Hacker M, Hoyer X, Kupzyk S, La Fougere C, Kois J, Stempfle HU, Tiling R, Hahn K, Störk S. Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging. 2006 Jun-Aug;22(3-4):407-16. [PubMed: 16328851]

43.Jain S, Londono FJ, Segers P, Gillebert TC, De Buyzere M, Chirinos JA. MRI Assessment of Diastolic and Systolic Intraventricular Pressure Gradients in Heart Failure. Curr Heart Fail Rep. 2016 Feb;13(1):37-46. [PubMed: 26780916]

44.Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013 Aug 30;113(6):660-75. [PubMed: 23989711]

45.Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA., American Heart Association Get With the Guidelines-Heart Failure Program. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32. [PubMed: 20123668]

46.Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O’Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW., VICTORIA Study Group. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021 Nov 16;10(22):e021094. [PMC free article: PMC8751950] [PubMed: 34743540]

47.Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM., VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. [PubMed: 32222134]

48.Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000 Dec;140(6):840-7. [PubMed: 11099986]

49.Rider I, Sorensen M, Brady WJ, Gottlieb M, Benson S, Koyfman A, Long B. Disposition of acute decompensated heart failure from the emergency department: An evidence-based review. Am J Emerg Med. 2021 Dec;50:459-465. [PubMed: 34500232]